Parallax Volatility Advisers, L.P. Viking Therapeutics, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$49.84 - $70.47 $5.31 Million - $7.51 Million	106,500 Added 208.01%	157,700 $9.98 Million
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $38,280 - $207,900	-2,200 Reduced 4.12%	51,200 $4.2 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $20,328 - $43,208	2,200 Added 4.3%	53,400 $993,000
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $9,828 - $14,400	900 Added 1.79%	51,200 $566,000
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $742,000 - $1.24 Million	50,000 Added 16666.67%	50,300 $815,000
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $2,424 - $5,198	300 New	300 $4,000
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $481,330 - $631,190	63,500 New	63,500 $632,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.